<DOC>
	<DOCNO>NCT02273973</DOCNO>
	<brief_summary>This two-arm , randomize , double-blind , multicenter , pre-operative study evaluate effect combine letrozole GDC-0032 ( also know taselisib ) versus letrozole placebo postmenopausal woman estrogen receptor-positive ( ER+ ) /human epidermal growth factor receptor 2 ( HER2 ) untreated , Stage I-III operable breast cancer . Participants randomize one two treatment arm 1:1 randomization ratio . Letrozole 2.5 milligram ( mg ) dose daily plus either Taselisib 4 mg ( two 2-mg tablet ) placebo 5 days-on/ 2 days-off schedule total 16 week .</brief_summary>
	<brief_title>A Study Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo Post-Menopausal Women With Breast Cancer ( LORELEI )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Female participant Postmenopausal status Histologically confirm invasive breast carcinoma , follow characteristic : ( ) Primary tumor great equal ( &gt; /= ) 2 centimeter ( cm ) large diameter ( cT13 ) MRI ; ( ii ) Stage I operable Stage III breast cancer ; ( iii ) Documented absence distant metastasis ( M0 ) Estrogen receptorpositive ( ER+ ) human epidermal growth factor receptor 2negative ( HER2 ) breast cancer Breast cancer eligible primary surgery Tumor tissue formalinfixed paraffinembedded core ( FFPE ) core biopsy breast primary tumor confirm evaluable phosphatidylinositol4,5bisphosphate 3kinase , catalytic subunit alpha ( PIK3CA ) mutation status central histopathology laboratory Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Fasting glucose less equal ( &lt; /= ) 125 milligram per deciliter ( mg/dL ) Adequate hematological , renal , hepatic function Absence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule Ability willingness comply study visit , treatment , test , comply protocol , investigator 's judgment Any prior treatment primary invasive breast cancer Participants cT4 cN3 stage breast tumor Bilateral invasive , multicentric , metastatic breast cancer Participants undergone excisional biopsy primary tumor and/or axillary lymph node sentinel lymph node biopsy Type 1 2 diabetes require antihyperglycemic medication Inability unwillingness swallow pill Malabsorption syndrome condition would interfere enteric absorption History prior currently active small large intestine inflammation ( Crohn 's disease ulcerative colitis ) . Any predisposition gastrointestinal ( GI ) toxicity require prior approval Medical Monitor . Congenital long QT syndrome QT interval correct use Fridericia 's formula ( QTcF ) &gt; 470 millisecond ( msec ) Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 60 % predict value Clinically significant ( i.e. , active ) cardiovascular disease , uncontrolled hypertension , unstable angina , history myocardial infarction , cardiac failure class IIIV Any contraindication MRI examination Active infection require intravenous antibiotic Participants require daily supplemental oxygen Clinically significant history liver disease , include viral know hepatitis , current alcohol abuse , cirrhosis Any disease , active uncontrolled pulmonary dysfunction , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , may affect interpretation result , render participant high risk treatment complication Significant traumatic injury within 3 week prior initiation study treatment Major surgical procedure within 4 week prior initiation study treatment Inability comply study followup procedure History malignancy within 5 year prior screen , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>